x

Posted 29 August, 2022

INTEGRA LIFESCIENCES HOLDINGS CORP appointed new CEO

CEO Change detected for ticker Nasdaq:IART in a 8-K filed on 29 August, 2022.


  On August 25, 2022, Integra LifeSciences Holdings Corporation (the "Company") announced that, consistent with the Company's succession planning following its CEO transition in late 2021, it will eliminate the position of Chief Operating Officer effective October 3, 2022.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of INTEGRA LIFESCIENCES HOLDINGS CORP
Health Care/Life Sciences • Medical Equipment/Supplies
Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. It operates under the Codman Specialty Surgical (CSS) and Tissue Technologies (TT) segments. The CSS segment includes technologies and instrumentation used for neurosurgery, neurocritical care, and otolaryngology. The TT segment focuses on complex wound surgery, surgical reconstruction, and peripheral nerve repair. The company was founded by Richard E. Caruso in 1989 and is headquartered in Princeton, NJ.
Market Cap
$2.87B
View Company Details
INTEGRA LIFESCIENCES HOLDINGS CORP by TradingView
Relevant filing section
ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS 

On August 25, 2022, Integra LifeSciences Holdings Corporation (the "Company") announced that, consistent with the Company's succession planning following its CEO transition in late 2021, it will eliminate the position of Chief Operating Officer effective October 3, 2022. Glenn Coleman, the Company's current Chief Operating Officer, will cease employment with the Company on that date.